Moderna Inc. on Sept. 1 asked the U.S. Food and Drug Administration to allow the use of a third booster dose of the company’s Covid-19 vaccine.

A new study may help explain why mRNA vaccines by Pfizer/BioNTech and Moderna are more effective at preventing hospitalizations and deaths than they are at preventing infection. In another study, preliminary data suggests certain cancer drugs may help protect patients with malignancies from being infected with the new coronavirus.

Moderna COVID vaccine

Moderna Inc. completed the real-time review process needed for a full approval for the company’s Covid-19 vaccine in people aged 18 years and older.

Inovio Pharmaceuticals Inc. is focused on launching the global late-stage trial of the company’s Covid-19 vaccine candidate in September 2021, chief executive Joseph Kim said in a call, with the drug developer expecting trial data in the first half of 2022.

Antibody levels in people inoculated with CanSino Biologics’ (CanSinoBIO) single-dose Covid-19 vaccine fell by some 30 percent after six months, however a booster shot could offer a significant lift, a senior executive said on Aug. 5.

Loxo Oncology, a division of Eli Lilly, and Kumquat Biosciences teamed up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specific immune responses in cancer patients.

Europe’s drug regulator started a real-time review of the Covid-19 vaccine developed by French drugmaker Sanofi and Britain’s GlaxoSmithKline, the fifth shot currently under such a review as of July 20.

Health agencies and vaccine and immunology experts have pushed back against Pfizer and BioNTech’s assertions that a Covid-19 booster shot is necessary.

Maryland-based Altimmune is discontinuing research into the clinical-stage biopharmaceutical firm’s intranasal Covid-19 vaccine following “disappointing” results. 

A mixed schedule of vaccines where a shot of Pfizer’s Covid-19 vaccine is given four weeks after an AstraZeneca shot will produce better immune responses than giving another dose of AstraZeneca, an Oxford study said on June 28.